Furthermore, the efficacy of cytotoxic T lymphocytes exposed to a mixture of TAAs, including survivin, is currently being tested in the treatment of hematological malignancies (clinical trial identifier NCT01333046, NCT02203903, NCT02475707). The gene discussed is BIRC5; the disease is hematologic disorder.